SalvaRx Group Plc (SALV.L) Share Price & News
- High-
- OPEN-
- VOL-
- MKT CAP-M
- LOW-
- CLOSE-
- SHARES IN ISSUE36.70M
SalvaRx Group Plc Company Profile
The SalvaRx Group is a drug discovery and development company focused on immune-oncology; SalvaRx invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies. The SalvaRx Group was founded by Drs. Ian Walters and Rob Kramer, two former Bristol-Myers Squibb drug developers with a history of championing immune-oncology and developing immune-oncology therapeutics. SalvaRx has a mandate to assemble and develop a portfolio of differentiated immune-oncology therapies for the treatment of late-stage cancers. SalvaRx provides its portfolio companies with operational support in addition to capital, sometimes operating its portfolio companies directly and sometimes augmenting the current team.